Mammalian Cell Fermentation Technology Market Size, Share & Trends Analysis Report By Type, By Application (Monoclonal Antibodies, Recombinant Proteins), By End-use, By Region, And Segment Forecasts, 2023 To 2030

Mammalian cell fermentation forms an integral part of biopharmaceutical production as the technology is commonly used for the manufacturing of various biosimilars, enzymes, vaccines, and other biologics. The technology involves the use of mammalian cells cultivated in-vitro with the help of cell culture media, which are further subjected to the process of fermentation in a bioreactor. During this process, the cells utilize several metabolic pathways to produce the desired end-products.

Most commonly used mammalian cells in this technology include the Chinese Hamster Ovary (CHO) cells, Human Embryonic Kidney (HEK) cells, Baby Hamster Kidney (BHK) cells, and others. For instance, CHO cells are used for the production of monoclonal antibodies such as Roche’s Perjeta (Pertuzumab), Amgen’s Aimovig (erenumab), and others, while HEK cells are used for the production of therapeutics such as Octapharma’s Vihuma (simoctocog alfa), Spark Therapeutics’ Luxturna (voretigene neparvovec-rzyl), and others.

The high extent of research and development (R&D) spending and several funding opportunities attracted by the biopharmaceutical industry are leading to the development of novel therapeutics with the help of mammalian cell fermentation technology. Furthermore, emerging biopharmaceutical companies are increasing the market expansion prospects due to their high R&D uptake and advancements in the technology used for biomanufacturing procedures. For instance, in 2021, emerging biopharmaceutical companies with an estimated R&D expenditure lower than USD 200 million and revenues less than USD 500 million annually, held around 65% of the molecules in the R&D pipeline, as compared to the 50% held around five years before. These factors can broaden the landscape of applications for biologics and fuel the demand for mammalian culture technology in the coming years.

The market is segmented based on type, application, end-use, and region. The type segment is divided into Chinese Hamster Ovary cell fermentation, Human Embryonic Kidney cell fermentation, Baby Hamster Kidney cell fermentation, murine myeloma cell fermentation, Medical Research Council Cell Strain - 5 fermentation, and others. The application segment is divided into monoclonal antibodies, recombinant proteins, biosimilars, vaccines, enzymes, and others. The end-use segment consists of biopharmaceutical companies, CMOs & CDMOs, and academic and research institutes.

The mammalian cell fermentation technology market is expected to witness a rapid growth over the forecast period due to the rising demand for novel and safe therapeutics in the North America, Europe, and Asia Pacific regions. In particular, countries such as the U.S., Canada, the UK, Germany, France, Japan, China, and India are anticipated to witness a high demand for mammalian culture bioprocessing technology due to the rapid economic growth and increasing healthcare spending in these regions. Furthermore, strategic initiatives undertaken by key market players are likely to boost the revenue generation opportunities in this market. For instance, in 2020, Culture Biosciences, a CDMO based in California, U.S., piloted their mammalian cell fermentation services for tapping into the growing market potential. Such initiatives are expected to broaden the growth prospects for the market in the near future

Mammalian Cell Fermentation Technology Market Segmentation

Key players operating in the market include Thermo Fisher Scientific, Inc.; Merck KGaA; Danaher; Lonza; Hoffmann-La Roche Ltd; Sartorius AG; AstraZeneca; Bristol-Myers Squibb; Amgen; Gilead Sciences; Moderna, Inc.; Regeneron Pharmaceuticals. These companies are involved in the development and marketing of mammalian cell-based fermentation technology products to meet the requirements of various end-users.